Respreeza - supply shortage

Resolved

alpha1-proteinase inhibitor (human)

Shortage information

The shortage affecting Respreeza has been resolved and the information and recommendations which were issued during the shortage no longer apply.

Key facts

• Medicines affected:
  Respreeza
• Supply shortage status:
  Resolved
• International non-proprietary name (INN) or common name:
  alpha1-proteinase inhibitor (human)
• Therapeutic area (MESH):
  • Genetic Diseases, Inborn
  • Lung Diseases
• Pharmaceutical forms affected:
  Powder and solvent for solution for infusion
• Strengths affected:
  • 1,000 mg
  • 4,000 mg
  • 5,000 mg
• Availability of alternatives:
  Yes

Key dates

• First published:
  25/02/2021
• Last updated:
  31/03/2021